{"id":"magnesium-sulfate-and-then-digoxin","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypermagnesemia (with magnesium sulfate)"},{"rate":null,"effect":"Digoxin toxicity (nausea, arrhythmias, visual disturbances)"},{"rate":null,"effect":"Hypokalemia exacerbation"},{"rate":null,"effect":"Bradycardia"},{"rate":null,"effect":"AV block"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Magnesium sulfate acts as an electrolyte replacement and antiarrhythmic agent, stabilizing cardiac membrane potential and reducing ectopic activity. Digoxin is a cardiac glycoside that inhibits the Na+/K+-ATPase pump, increasing intracellular calcium and enhancing myocardial contractility while also slowing conduction through the AV node via vagomimetic effects. Together, they may be used sequentially to manage acute arrhythmias and heart failure.","oneSentence":"Magnesium sulfate reduces cardiac arrhythmias and electrolyte imbalance, while digoxin increases cardiac contractility and slows atrioventricular conduction.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:20:02.270Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute arrhythmias with hypomagnesemia"},{"name":"Heart failure with reduced ejection fraction"},{"name":"Atrial fibrillation rate control"}]},"trialDetails":[{"nctId":"NCT05287191","phase":"PHASE3","title":"MAGNAM Trial, Magnesium Versus Amiodarone in Atrial Fibrillation in Critical Care","status":"RECRUITING","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2022-01-05","conditions":"Atrial Fibrillation New Onset","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":31,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Magnesium sulfate and then Digoxin","genericName":"Magnesium sulfate and then Digoxin","companyName":"Sunnybrook Health Sciences Centre","companyId":"sunnybrook-health-sciences-centre","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Magnesium sulfate reduces cardiac arrhythmias and electrolyte imbalance, while digoxin increases cardiac contractility and slows atrioventricular conduction. Used for Acute arrhythmias with hypomagnesemia, Heart failure with reduced ejection fraction, Atrial fibrillation rate control.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}